Evaluation of ß2‐Microglobulin Removal with High‐Performance Hemodiafiltration

Publisher Website
Google Scholar
Abstract
Several lines of evidence suggest that ß2‐mi‐croglobulin (ß2M) accumulation in long‐term hemodialysis (HD) patients results in so‐called dialysis‐associated amyloidosis (DAA), which is clinically manifested by carpal tunnel syndrome, osteoarthropathy, and the other organ involvements. For the purpose of preventing the ß2M accumulation, the efficiency of (ß2M removal during hemodiafiltration (HDF) with high‐performance membranes (HPM), hemofiltration (HF), HD, and charcoal hemoperfusion was evaluated. Among 27 patients treated with these methods, significant (ß2M removal was noted in HDF with HPM and HD with polyacrylonitril (PAN) membrane. However, treatment of HDF with HPM for more than 6 months caused no remarkable improvement in clinical symptoms of patients, and serum ß2M levels decreased in only two out of 15 patients. These results imply that ß2M might be most effectively removed by HDF with HPM and HD with PAN membrane, but further long‐term studies will be necessary to conclude whether these procedures could become successful therapeutic regimen for DAA.